search
Back to results

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
lixisenatide AVE0010
biguanide
TZD
alpha-GI
glinide
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria :

  • Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening visit
  • Patient treated for at least 3 months prior to screening visit with one of following OADs at a stable dose of at least usual maintenance dose as described in the label

    • a biguanide (metformin hydrochloride);
    • a thiazolidinedione (TZD) (pioglitazone hydrochloride);
    • an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol);
    • or a glinide (nateglinide, repaglinide or mitiglinide);
  • Signed written informed consent

Exclusion criteria:

  • At screening HbA1c <7% or >9.5%;
  • At screening: fasting plasma glucose >250 mg/dL (>13.9 mmol/L);
  • Use of any glucose-lowering agent(s) other than the authorized patient's background treatment defined in I02 (as given in inclusion critieria) within 3 months prior to screening;
  • Type 1 diabetes mellitus;
  • Women of childbearing potential with no effective contraceptive method;
  • Pregnancy or lactation;
  • Laboratory findings at the time of screening:

    • Amylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN);
    • ALT >3 ULN;
  • Any contra-indication to the patient's background oral anti-diabetic treatment;
  • History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease;
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);
  • Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 392335
  • Investigational Site Number 392325
  • Investigational Site Number 392328
  • Investigational Site Number 392326
  • Investigational Site Number 392327
  • Investigational Site Number 392310
  • Investigational Site Number 392336
  • Investigational Site Number 392314
  • Investigational Site Number 392334
  • Investigational Site Number 392304
  • Investigational Site Number 392306
  • Investigational Site Number 392307
  • Investigational Site Number 392301
  • Investigational Site Number 392312
  • Investigational Site Number 392302
  • Investigational Site Number 392324
  • Investigational Site Number 392331
  • Investigational Site Number 392332
  • Investigational Site Number 392329
  • Investigational Site Number 392322
  • Investigational Site Number 392333
  • Investigational Site Number 392330
  • Investigational Site Number 392320
  • Investigational Site Number 392303
  • Investigational Site Number 392311
  • Investigational Site Number 392316
  • Investigational Site Number 392319

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Lixisenatide + Biguanide

Lixisenatide + TZD

Lixisenatide + alpha-GI

Lixisenatide + Glinide

Arm Description

52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)

52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)

52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)

52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)

Outcomes

Primary Outcome Measures

Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data

Secondary Outcome Measures

Absolute change in HbA1c
Absolute change in fasting plasma glucose
Absolute change in body weight

Full Information

First Posted
September 9, 2013
Last Updated
August 3, 2015
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01940965
Brief Title
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Official Title
An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: The primary objective of this study is to assess the overall safety of lixisenatide once daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in patients with type 2 diabetes in Japan. Secondary Objective: To assess the effects of lixisenatide in combination with background oral antidiabetic drug (OAD) on: HbA1c; Fasting plasma glucose; Body weight.
Detailed Description
54 weeks +/-11 days

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
294 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lixisenatide + Biguanide
Arm Type
Experimental
Arm Description
52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
Arm Title
Lixisenatide + TZD
Arm Type
Experimental
Arm Description
52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
Arm Title
Lixisenatide + alpha-GI
Arm Type
Experimental
Arm Description
52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
Arm Title
Lixisenatide + Glinide
Arm Type
Experimental
Arm Description
52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
Intervention Type
Drug
Intervention Name(s)
lixisenatide AVE0010
Intervention Description
Pharmaceutical form:solution Route of administration: Subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
biguanide
Intervention Description
Pharmaceutical form:tablet Route of administration: oral
Intervention Type
Drug
Intervention Name(s)
TZD
Intervention Description
Pharmaceutical form:tablet Route of administration: oral
Intervention Type
Drug
Intervention Name(s)
alpha-GI
Intervention Description
Pharmaceutical form:tablet Route of administration: oral
Intervention Type
Drug
Intervention Name(s)
glinide
Intervention Description
Pharmaceutical form:tablet Route of administration: oral
Primary Outcome Measure Information:
Title
Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Absolute change in HbA1c
Time Frame
From baseline to weeks 24 and 52
Title
Absolute change in fasting plasma glucose
Time Frame
From baseline to weeks 24 and 52
Title
Absolute change in body weight
Time Frame
From baseline to weeks 24 and 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria : Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening visit Patient treated for at least 3 months prior to screening visit with one of following OADs at a stable dose of at least usual maintenance dose as described in the label a biguanide (metformin hydrochloride); a thiazolidinedione (TZD) (pioglitazone hydrochloride); an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol); or a glinide (nateglinide, repaglinide or mitiglinide); Signed written informed consent Exclusion criteria: At screening HbA1c <7% or >9.5%; At screening: fasting plasma glucose >250 mg/dL (>13.9 mmol/L); Use of any glucose-lowering agent(s) other than the authorized patient's background treatment defined in I02 (as given in inclusion critieria) within 3 months prior to screening; Type 1 diabetes mellitus; Women of childbearing potential with no effective contraceptive method; Pregnancy or lactation; Laboratory findings at the time of screening: Amylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN); ALT >3 ULN; Any contra-indication to the patient's background oral anti-diabetic treatment; History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease; Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes); Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 392335
City
Adachi-Ku
Country
Japan
Facility Name
Investigational Site Number 392325
City
Chiba-Shi
Country
Japan
Facility Name
Investigational Site Number 392328
City
Chiyoda-Ku
Country
Japan
Facility Name
Investigational Site Number 392326
City
Chuo-Ku
Country
Japan
Facility Name
Investigational Site Number 392327
City
Chuo-Ku
Country
Japan
Facility Name
Investigational Site Number 392310
City
Chuoh-Ku
Country
Japan
Facility Name
Investigational Site Number 392336
City
Kagoshima-Shi
Country
Japan
Facility Name
Investigational Site Number 392314
City
Kamakura-Shi
Country
Japan
Facility Name
Investigational Site Number 392334
City
Kashiwara-Shi
Country
Japan
Facility Name
Investigational Site Number 392304
City
Kawagoe-Shi
Country
Japan
Facility Name
Investigational Site Number 392306
City
Kawaguchi-Shi
Country
Japan
Facility Name
Investigational Site Number 392307
City
Kisarazu-Shi
Country
Japan
Facility Name
Investigational Site Number 392301
City
Koriyama-Shi
Country
Japan
Facility Name
Investigational Site Number 392312
City
Mitaka-Shi
Country
Japan
Facility Name
Investigational Site Number 392302
City
Mito-Shi
Country
Japan
Facility Name
Investigational Site Number 392324
City
Mito-Shi
Country
Japan
Facility Name
Investigational Site Number 392331
City
Nagoya-Shi
Country
Japan
Facility Name
Investigational Site Number 392332
City
Nagoya-Shi
Country
Japan
Facility Name
Investigational Site Number 392329
City
Ohta-Ku
Country
Japan
Facility Name
Investigational Site Number 392322
City
Okawa-Shi
Country
Japan
Facility Name
Investigational Site Number 392333
City
Osaka-Shi
Country
Japan
Facility Name
Investigational Site Number 392330
City
Sagamihara-Shi
Country
Japan
Facility Name
Investigational Site Number 392320
City
Saijo-Shi
Country
Japan
Facility Name
Investigational Site Number 392303
City
Sakado-Shi
Country
Japan
Facility Name
Investigational Site Number 392311
City
Shinjuku-Ku
Country
Japan
Facility Name
Investigational Site Number 392316
City
Shizuoka-Shi
Country
Japan
Facility Name
Investigational Site Number 392319
City
Suita-Shi
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs